YAP1 and renal cell carcinoma: Since YAP and TAZ orchestrate several downstream effects, including EMT, migration, proliferation, tumor growth, angiogenesis, and immune evasion (see Figure 2 and Figure 3), YAP/TAZ targeting could be a novel and viable approach to slow RCC progression.